Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stella Pharma Corporation

http://en.stella-pharma.co.jp

Latest From Stella Pharma Corporation

Rocky Road To Glioma Approval: BNCT Firm Stella Redesigns Japan PII Trial

Japanese bioventure Stella Pharma is re-designing a Phase II trial for its glioma candidate Steboronine after it was determined the original primary endpoint was not robust enough to prove efficacy, a challenge faced by some others working in the difficult indication. The drug was approved for head and neck cancer in Japan in 2020 and Stella has already announced a new collaboration which may be key to moving forward. 

Japan Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Diversified
  • Pharmaceuticals
  • Pharmaceuticals
    • Chiral Chemistry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
UsernamePublicRestriction

Register